Abbott reports positive trial data for Absorb vascular scaffold

Abbott has published positive clinical data that demonstrates the effectiveness of its innovative new Absorb bioresorbable vascular scaffold.

Results from the second phase of an ongoing study, also called Absorb, have shown a low rate of major adverse cardiac events and blood clots after a one-year period among the 101 patients using the device.

Moreover, nearly all of those trialled using the device showed signs of vasomotion after 12 months, suggesting that the scaffold had started to be metabolised, thereby removing the constraints on vessels.

Dr Charles Simonton, divisional vice-president of medical affairs and chief medical officer at Abbott Vascular, said: "The positive one-year clinical results from the Absorb trial provide support for the clinical performance of the device and its potential to change the way coronary artery disease is treated."

Earlier this month, the company published analysis of data from a number of drug-eluting stent trials that demonstrate the clinical efficacy of its Xience V system.